Brief: Aileron Therapeutics And Advancium Health Network Announce An Exclusive Option Agreement For The Acquisition Of ALRN-6924 For Retinoblastoma
31/10/2024 11:34
Oct 31 (Reuters) - Aileron Therapeutics Inc ALRN.O :
* AILERON THERAPEUTICS AND ADVANCIUM HEALTH NETWORK ANNOUNCE
AN
EXCLUSIVE OPTION AGREEMENT FOR THE ACQUISITION OF ALRN-6924 FOR
RETINOBLASTOMA
Source text: ID:nPn99bSwra
Further company coverage: ALRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering